NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Citigroup
Stock analysts at Citigroup started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $42.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 130.77% from the stock’s current price. Other analysts […]
Stock analysts at Citigroup started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $42.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 130.77% from the stock’s current price. Other analysts […]
